08:29 EDT SNTA Synta Pharmaceuticals price target raised to $27 from $20 at Roth Capital
Subscribe for More Information
08:13 EDT SNTA Synta Pharmaceuticals price target raised to $14 from $11 at JMP Securities
JMP Securities increased its price target on Synta as the firm believes that recent data from a trial of the company's cancer treatment ganetespib bodes well for an ongoing trial of the drug. The firm reiterates an Outperform rating on the shares.